| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
We identified HLA-A24-restricted and SPARC-derived CTL epitope peptides. By using these peptides, we tried to induce HLA-A24 (A*2402) -restricted and SPARC-reactive human CTLs, and demonstrate an antitumor immune response.The SPARC peptides-reactive CTLs were successfully induced from PBMCs of positive healthy donors and cancer patients by in vitro stimulation, and these CTLs exhibited cytotoxicity specific to cancer cells expressing both SPARC and HLA-A24. The adoptive transfer of the SPARC-specific CTLs could inhibit the tumor growth in NOD/SCID mice bearing human cancer cells expressing both HLA-A24 and SPARC.These findings suggest that SPARC is a potentially useful target candidate for cancer immunotherapy.
|
